Chlorambucil targets BRCA1/2-deficient tumours and counteracts PARP inhibitor resistance. (2019)

Abstract

No abstract provided

Bibliographic Information

Digital Object Identifier: http://dx.doi.org/10.15252/emmm.201809982

PubMed Identifier: 31273933

Publication URI: http://europepmc.org/abstract/MED/31273933

Type: Journal Article/Review

Volume: 11

Parent Publication: EMBO molecular medicine

Issue: 7

ISSN: 1757-4676